MedWaves' AveCure microwave coagulation-ablation (MWA) system uses microwave energy to volumetrically coagulate-ablate (destroy) soft-tissue lesions (abnormal structures) safely, effectively, precisely and with repeatability. The system has successfully treated over 1,000 patients worldwide, including lesions in bone, kidney, liver, lung and pancreas. The company plans to bring its technology to treat lesions in other locations in the body. The company's technology makes available treatment options for many cancer patients in either early or late stage and helps those who are running out of options.

Taiwan, with over 23 million in population, is one of 15 highly developed Asian countries in the region, an important market for MedWaves. As with other developed countries in the region, its cancer incidence rate is on the rise, and cancer remains the leading cause of death in Taiwan as its life expectancy continues to rise according to Taiwan Today, June 2011. The five most common types of cancer in 2008 were colon, liver, lung, breast and oral cancer according to Taiwan Central News Agency, April 2011. MedWaves is pleased to announce the receipt of TFDA certification to import and sell its products to help those in need. MedWaves will work in close coordination with its Taiwanese distributor-partners to schedule and conduct clinical evaluations for the sale of its AveCure system in key hospitals in Taiwan. Earlier this year, Hong Kong University published its successful treatment of tumours in the liver using the MedWaves AveCure microwave ablation system. The Hong Kong University has adopted the MedWaves AveCure system as a cancer treatment tool.

MedWaves AveCure Microwave Coagulation-Ablation System overcomes the limitations of other microwave and radiofrequency (RF) thermal ablation technologies to destroy lesions safely, effectively, precisely and with repeatability and uniformity. It is the only system approved in the market to provide clinicians with patented, fully integrated real-time temperature, both forward and reverse-power feedback to control energy delivery intelligently. The system, which consists of a generator, extension cable set, and an array of single-patient-use microwave-probe devices, enables the surgeons and interventional radiologists to treat soft-tissue lesions, such as tumours, safely and easily, with confidence. This single-patient-use device provides MedWaves with a continuous growth of revenue stream.

MedWaves AveCure Microwave Coagulation-Ablation System has also received US FDA approval for sales in the United States, CE Mark for sales in the European Union, KFDA certification for import and sales in Korea, and SFDA certification for import and sales in China. Other received approval and certification announcements to follow.

MedWaves, Inc., a United States company based in San Diego, California, develops innovative and proprietary microwave ablation technology for the minimally invasive coagulation-ablation products for soft tissue lesions, such as tumours.